Anticoagulation quality assessment in non-valvular atrial fibrillation hospitalized patients

• Autores: M.A. Hermida Ayala, J.F. Sierra Sánchez, Y. Castellanos Clemente, E. Velasco Rojas, A. Andrés Rosado
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 1, 2014, págs. 31-36
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: The purpose of this study was to determine the quality of antithrombotic treatment in hospitalized atrial fibrillation patients and the possible role of the new oral anticoagulants in the improvement of this therapy. Method: A prospective analysis of non-valvular atrial fibrillation patients was performed. For each patient, antithrombotic treatment quality was assessed using as quality criteria the coexistence of need, effectiveness and safety. In patients whom a suboptimal quality of anticoagulation was found, it was determined the role of new oral anticoagulants as dabigatran and rivaroxaban could have in the improvement of their therapy. Results: During a period of two months, a total of 44 hospital admissions were analyzed. A 77% (n = 34) were receiving antithrombotic treatment. This treatment had an optimal quality in the 33% of the patients (n = 11). New oral anticoagulants could have a role in the improvement of anticoagulation quality in a 65% (n = 15) of patients. Conclusions: In non-valvular atrial fibrillation hospitalized patients the anti-coagulant treatment is of deficient quality. In those cases, the new oral anticoagulants could be an alternative for improving anticoagulation quality